Galectin 3 complements BNP in risk stratification in acute heart failure

Gregory J. Fermann, Christopher J. Lindsell, Alan B. Storrow, Kimberly Hart, Matthew Sperling, Susan Roll, Neal L. Weintraub, Karen F. Miller, David J. Maron, Allen J. Naftilan, John A. McPherson, Douglas B. Sawyer, Robert Christenson, Sean P. Collins

Research output: Contribution to journalArticlepeer-review

45 Scopus citations


Background: Galectin 3 (G3) is a mediator of fibrosis and remodeling in heart failure. Methods: Patients diagnosed with and treated for Acute Heart Failure Syndromes were prospectively enrolled in the Decision Making in Acute Decompensated Heart Failure multicenter trial. Results: Patients with a higher G3 had a history of renal disease, a lower heart rate and acute kidney injury. They also tended to have a history of HF and 30-day adverse events compared with B-type natriuretic peptide. Conclusion: In Acute Heart Failure Syndromes, G3 levels do not provide prognostic value, but when used complementary to B-type natriuretic peptide, G3 is associated with renal dysfunction and may predict 30-day events.

Original languageEnglish (US)
Pages (from-to)706-713
Number of pages8
Issue number8
StatePublished - Dec 2012


  • Acute heart failure
  • Renal disease
  • Risk stratification

ASJC Scopus subject areas

  • Biochemistry
  • Clinical Biochemistry
  • Health, Toxicology and Mutagenesis


Dive into the research topics of 'Galectin 3 complements BNP in risk stratification in acute heart failure'. Together they form a unique fingerprint.

Cite this